Neoplasia hematologikoak: Leuzemiak, Linfomak eta Mielomak

DOSAGE REGIMEN FOR REDUCING CYTOKINE RELEASE SYNDROME (CRS) WITH ANTI-FCRH5/ANTI-CD3 BISPECIFIC ANTIBODIES IN MULTIPLE MYELOMA THERAPY

Resumen de: WO2026030464A1

The disclosure provides methods of dosing for the treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CDS) bispecific antibodies (e.g., cevostamab).

MICROCRYSTALLINE POLYMORPHS OF LMP744 AND USES THEREOF

Resumen de: WO2026029972A1

Disclosed herein are crystalline polymorphs of LMP744 that can be used in the treatment of cancers associated with dysregulation of Top1 and/or MYC activity, such as, for example, a sarcoma, (e.g., Ewing's sarcoma), a carcinoma, a hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, non-small cell lung carcinoma, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, a melanoma, a glioma, leukemia, a lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, and plasma cell neoplasm (myeloma). This abstract is intended as a scanning tool for purposes of searching m the particular art and is not intended to be limiting of the present invention.

ALK MUTATIONS AND USES THEREOF

Resumen de: WO2026030539A1

Provided herein are mutant anaplastic lymphoma kinase (ALK) nucleic acid molecules and polypeptides, methods related to detecting mutant ALK nucleic acid molecules and polypeptides in cancer, as well as methods of treatment, uses, systems, and non-transitory computer-readable storage media related thereto. A mutant ALK nucleic acid molecule or polypeptide of the present disclosure can be used to identify cancers that are more likely to be resistant to ALK-targeted therapies, or individuals that may benefit from a change in ALK- targeted therapy-based treatment.

TREATING MULTIPLE MYELOMA WITH ANTI-CD3/BCMA BISPECIFIC ANTIBODY IN COMBINATION WITH AN ANTI-CD38 ANTIBODY

Resumen de: WO2026030537A1

Methods of treating relapsed or refractory multiple myeloma by administering (a) a bispecific antibody that binds to CD3 and BCMA. and (b) an anti-CD38 antibody (e.g., daratumumab) to a patient in need are provided.

METHOD OF USING ANTI-CD79b IMMUNOCONJUGATES

Resumen de: AU2026200119A1

22350466_1 (GHMatters) P106885.AU.2 Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti- CD79b antibodies in combination with additional therapeutic agents. an a n

MICROCRYSTALLINE POLYMORPHS OF LMP400 AND USES THEREOF

Resumen de: WO2026029971A1

Disclosed herein are crystalline polymorphs of indotecan (LMP400) that can be used in the treatment of cancers associated with dysregulation of Topl and/or MYC activity, such as, for example, a sarcoma, (e.g., Ewing's sarcoma), a carcinoma, a hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, non-small cell lung carcinoma, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, a melanoma, a. glioma, leukemia, a lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, and plasma cell neoplasm (myeloma). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

SIRNA FOR INHIBITING KRAS GENE EXPRESSION, AND MODIFIED FORM THEREOF AND USE THEREOF

Resumen de: WO2026026715A1

The present application belongs to the field of biomedicine. Disclosed are an siRNA for inhibiting KRAS gene expression, and a modified form thereof and the use thereof. Provided in the present application is a double-stranded RNA molecule targeting KRAS, wherein the molecule can treat KRAS-associated diseases such as metastatic non-small cell lung cancer, metastatic pancreatic ductal adenocarcinoma, KRAS G12C+ non-small cell lung cancer, diabetic retinopathy, leukemia, cholangiocarcinoma, metastatic colorectal cancer, gastric cancer, advanced non-small cell lung cancer, stage-IV non-small cell lung cancer, gastric adenocarcinoma, sepsis, KRAS G12C-mutated advanced non-small cell lung cancer and gallbladder cancer.

Pralatrexate and cop combination for the treatment of patients with peripheral t cell lymphoma

Resumen de: AU2024296708A1

Methods for treating peripheral T-cell lymphoma include administering to a subject a combination of Cyclophosphamide, Vincristine, Prednisone, and Pralatrexate, wherein the combination does not include doxorubicin. The treatment may be administered in repeated three-week cycles, optionally including a drug holiday.

POLYFLUORINATED THALIDOMIDE ANALOGS AND USES THEREOF

Resumen de: AU2024321683A1

Polyfluorinated thalidomide analogs have a structure according to formula I, wherein R is aliphatic. The compounds may be used to inhibit cancer cell proliferation and/or to treat subjects with cancer or an inflammatory process. In some aspects, the cancer is multiple myeloma. In certain aspects, the compounds are used to inhibit proliferation of drug-resistant multiple myeloma cells and/or to treat subjects with drug-resistant multiple myeloma.

DILUTED CARFILZOMIB FOR USE IN TREATING MULTIPLE MYELOMA

Resumen de: AU2024321532A1

Provided herein are methods for treating a disease or condition selected from the group consisting of cancer, autoimmune disease, graft or transplant-related condition, neurodegenerative disease, fibrotic-associated condition, ischemic-related conditions, infection (viral, parasitic or prokaryotic) and diseases associated with bone loss, the method comprising administering to a patient a therapeutically effective amount of carfilzomib or a pharmaceutically acceptable salt thereof at a dose volume of 10 mL/kg or higher. Also provided herein are methods for treating multiple myeloma in a patient, comprising administering to the patient a pharmaceutical composition comprising carfilzomib or a pharmaceutically acceptable salt thereof and an aqueous carrier, wherein the carfilzomib is administered at a dose volume of 2.5 mL/kg or higher and/or at a concentration of less than 2 mg/mL.

TREATMENT OF MULTIPLE MYELOMA

Resumen de: US20260027084A1

The present disclosure provides methods of treating multiple myeloma in a patient in need thereof comprising administering a gamma secretase and a B-cell maturation antigen (BCMA)-directed therapy to the patient.

COMPOSITIONS AND METHODS FOR INHIBITING DNMT1 METHYLATION ACTIVITY FOR REDUCING CHEMOTHERAPY INDUCED AMPLIFICATION AND REARRANGEMENT IN MIXED LINEAGE LEUKEMIA (MLL)

Resumen de: WO2026025099A1

Compositions and methods for control of DNMT1-mediated site-specific copy gains and genomic insertions associated with mixed lineage leukemia are provided.

NUCLEIC ACIDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNE CELL ENGAGERS

Resumen de: WO2026025111A1

The present disclosure relates to novel nucleic acids for an immune cell engagers, comprising a ribonucleic acid of formula I: R1 - SP - R2 - R3 - R4 - R5 (I), where R1 is a 5' untranslated region (UTR); SP encodes a signal peptide; R2 encodes a first single chain variable fragment (scFv) that binds a first extracellular protein or a variable region of a heavy chain (VH-only) that binds a first extracellular protein; R3 encodes a second scFv that binds a second extracellular protein; R4 encodes a half-life extender; R5 is a 3'UTR, and where R1 to R5 are oriented 5' to 3', for the treatment of cancers, including but not limited to hematological cancers, including multiple myeloma.

Chimeric antigen receptors with BCMA specificity and uses thereof

Resumen de: AU2026200174A1

B-cell maturation antigen (BCMA) is expressed on malignant plasma cells. The present invention provides BCMA-specific chimeric antigen receptors and cells expressing such chimeric antigen receptors. In certain embodiments, engineered cells expressing the chimeric antigen receptors of the present invention are capable of inhibiting the growth of tumors expressing BCMA. The engineered cells of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced BCMA-targeted immune response is desired and/or therapeutically beneficial. For example, engineered cells expressing the BCMA-specific chimeric antigen receptors of the invention are useful for the treatment of various cancers, including multiple myeloma. an a n

CEREBLON LIGASE MODULATOR AND BCMA NK CELL ENGAGER COMBINATION THERAPY

Resumen de: WO2026022712A1

The present disclosure relates to a method of treating cancer (e.g., multiple myeloma) with the combination of i) a multifunctional binding protein comprising a first and a second antigen binding domains (ABDs), wherein the first ABD binds specifically to human BCMA and the second ABD binds specifically to human NKp46; and ii) a cereblon modulating agent.

METHODS OF TREATING LEUKEMIA USING CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS

Resumen de: WO2026024976A1

The present disclosure relates to methods of treating leukemia using a heterobifunctional molecule, referred to as a cytotoxicity targeting chimera (CyTaC) or antibody recruiting molecule (ARM), that is able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein.

GARP AS A BIOMARKER AND BIOTARGET IN T-CELL MALIGNANCIES

Resumen de: US20260029402A1

The present study of the regulatory T phenotype of Sézary cells led to the discovery of the expression of GARP (LRRC32) by Sézary cells. GARP has also been shown to be overexpressed in samples from patients with acute lymphoblastic leukemia. GARP therefore appears as a diagnostic marker, for monitoring T-cell malignancies, and as a therapeutic target. Accordingly, the present invention relates to methods for the diagnosis and treatment of T-cell malignancies.

HIGH SURFACE-AREA LYOPHILIZED COMPOSITIONS COMPRISING ARSENIC FOR ORAL ADMINISTRATION IN PATIENTS

Resumen de: US20260027056A1

The present invention relates to treating malignancies such as tumors or cancers by orally administering lyophilized compositions comprising arsenic to a subject in such need. Malignancies include various hematological malignancies, such as acute myeloid leukemia (AML) including acute promyelocytic leukemia (APL), myelodysplastic syndrome (MDS), multiple myeloma (MM) and lymphomas and solid tumors including glioblastoma multiforme and breast cancer. This invention relates to a novel formulation comprising a lyophilized compositions comprising arsenic. The present invention also relates to a method for lyophilizing the arsenic trioxide, preparing the oral formulation comprising lyophilized compositions comprising arsenic, and a method for treating a subject with malignancies using the oral formulation.

MUTATION AND CELL STATE COOPERATION DRIVES PROGRESSION AND IS A TARGETABLE FEATURE OF REMISSION IN ACUTE LYMPHOBLASTIC LEUKEMIA

Resumen de: WO2026024988A1

Methods for treating leukemia are disclosed based on detecting specific cell states and transcriptional programs within leukemic cells. This disclosure presents a novel therapeutic method for treating acute lymphoblastic leukemia (ALL), including BCR-ABL positive and BCR-ABL1-like ALL subtypes. The method involves detecting specific cell states and transcriptional programs in patient samples and administering targeted therapies based on these characteristics. For a pre-B cell-like state or pre-BCR signaling program, a combination of tyrosine kinase inhibitor (TKI) and SYK inhibitor is used. Conversely, a progenitor-like state or stress-autophagy program is treated with a TKI and a p38 MAPK inhibitor. This approach aims to improve treatment efficacy by tailoring therapy to the leukemia's unique molecular and cellular features, particularly in relapsed cases or when minimal residual disease is present.

ENABLE DISCOVERY OF BCL-2 FAMILY INHIBITORS TARGETING MODE II COMPLEXES

Resumen de: WO2026025080A1

This application generally relates to pro-survival complex between a guardian and an effector assembled from their intact BCL-2 globular core domains. In particular, the disclosure relates to methods of identifying modulators of BCL2 antagonist/killer (BAK) binding of Myeloid cell leukemia-1 (MCL-1).

GENETICALLY ENGINEERED MICE MODELS FOR MULTIPLE MYELOMA

Resumen de: US20260026479A1

The invention relates to genetically engineered mouse models for multiple myeloma (MM) and their uses thereof for the development of multiple myeloma models as well as for the screening of compounds suitable for the treatment of multiple myeloma.

IKZF2 AND CK1-ALPHA DEGRADING COMPOUNDS AND USES THEREOF

Resumen de: US20260021103A1

Provided herein are compounds that promote targeted degradation of IKZF1, IKZF2, GSPT1, and/or CK1a, proteins whose activities are implicated in the pathology of certain cancers (e.g., acute myeloid leukemia). Also provided are pharmaceutical compositions comprising the compounds. Also provided are methods of treating cancer, and methods of promoting the degradation of IKZF1, IKZF2, GSPT1, and/or CK1a in a subject or biological sample by administering a compound or composition described herein.

COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND IMMUNOMODULATORY DRUGS

Resumen de: US20260021093A1

The invention relates to combinations comprising an HDAC inhibitor and an immunomodulatory drug for the treatment of multiple myeloma in a subject in need thereof. The combinations may, optionally, further comprise an anti-inflammatory agent, such as dexamethasone. Also provided herein are methods for treating multiple myeloma in a subject in need thereof comprising administering to the subject an effective amount of one of the above combinations.

METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES TO TREAT FOLLICULAR LYMPHOMA

Resumen de: US20260021088A1

Provided herein are methods of treating B-cell proliferative disorders (such as Follicular Lymphoma “FL”) using immunoconjugates comprising anti-CD79b antibodies in combination with an immunomodulatory agent (such as lenalidomide) and an anti-CD20 antibody (such as obinutuzumab or rituximab).

COMPOUNDS THAT RE-ACTIVATE MUTANT P53

Nº publicación: AU2024275892A1 22/01/2026

Solicitante:

INSTITUTE FOR CANCER RES D/B/A THE RES INSTITUTE OF FOX CHASE CANCER CENTER
INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER

Resumen de: AU2024275892A1

The present disclosure is concerned with compounds that restore p53 activity and methods of using the compounds in the treatment of various disorders related to loss of p53 activity such as, for example, cancer (e.g, a sarcoma, a carcinoma, a head-and-neck cancer, hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanoma, a glioma, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, non-small cell lung carcinoma, small cell lung carcinoma, renal cancer, lung cancer, colon cancer, cervical cancer, and plasma cell neoplasm (myeloma)). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.